The corporate venturing unit of life sciences company Eli Lilly and chemicals group BASF, could realise its investment in Receptos, a US-based therapeutics company planning its flotation. Receptos has filed for an $86.3m initial public offering on the Nasdaq stock exchange. Investment banks Credit Suisse, Leerink Swann and BMO Capital Markets are lead underwriters. To…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
